Discounted Cash Flow
Zevra Therapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $0 | $-16.5m | $-30.4m | — | $-1.13 |
| 2017 | $0 | $-43.4m (-162.7%) | $-33.3m (-9.4%) | — | $-2.96 (-161.9%) |
| 2018 | $0 | $-56.5m (-30.1%) | $-54.2m (-62.9%) | — | $-3.15 (-6.4%) |
| 2019 | $12.8m | $-24.5m (56.6%) | $-23.8m (56.2%) | -191.0% | $-0.83 (73.7%) |
| 2020 | $13.3m (3.5%) | $-12.8m (48.0%) | $-2.0m (91.7%) | -96.0% (49.7%) | $-3.21 (-286.7%) |
| 2021 | $28.6m (115.6%) | $-8.6m (33.0%) | $10.3m (624.2%) | -29.9% (68.9%) | $-2.11 (34.3%) |
| 2022 | $10.5m (-63.5%) | $-41.5m (-385.6%) | $-18.8m (-282.0%) | -397.2% (-1230.3%) | $-1.20 (43.1%) |
| 2023 | $27.5m (162.6%) | $-46.0m (-10.8%) | $-33.8m (-79.9%) | -167.7% (57.8%) | $-1.30 (-8.3%) |
| 2024 | $23.6m (-14.0%) | $-105.5m (-129.1%) | $-69.7m (-105.9%) | -446.9% (-166.5%) | $-2.28 (-75.4%) |
| 2025 | $106.5m (350.9%) | $83.2m (178.9%) | $-2.4m (96.5%) | 78.2% (117.5%) | $1.40 (161.4%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.